INTEGRATE phase II trial: regorafenib vs. placebo in pretreated metastatic gastric cancer patients—is there anything new?

Gastric cancer ranks among the most frequent cancers and the third leading cause of cancer mortality in both sexes worldwide (1,2). Unfortunately in western Countries the majority of gastric tumours are diagnosed in an advanced stage, when outcome remains disappointing. In this setting chemotherapy still represents the standard of care with the notable exception of trastuzumab use in HER-2 over-expressing tumours (3-7). Recent progresses in the molecular characterization of gastric adenocarcinomas opened new insight for new treatment possibilities to be hopefully explored in the near future (8).